Tesamorelin

替莫瑞林

Report date: 2026/05/20 20:02:01
First In Class

Base Information

Drug NameTesamorelin
Drug Alias Nametesamorelina特莫瑞林tesamorelinumEgriftaTH-9507
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGrowth hormone releasing factor agonists
TargetsGrowth hormone releasing factor
Therapy Area/IndicationsGrowth hormone deficiencyCognitive DysfunctionHealthy Aging +[14] 
Global Approved IndicationsLipodystrophy
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2010/11/10
Country/TerritoryBelgiumCanadaUnited States +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTheratechnologies Inc
China Registration ClassN/A

Develop Information

Active CompaniesHudson BiotechWorld Orphan Drug AllianceTheratechnologies Inc +[7] 
Inactive CompaniesNational Institute Of Nursing ResearchUniversity Of Texas Medical BranchNational Heart, Lung, And Blood Institute (Nhlbi) +[4] 
Active IndicationsCognitive DysfunctionHealthy AgingFrailty +[9] 
Inactive IndicationsGrowth hormone deficiencyDiabetes Mellitus, Type 2Sleep Wake Disorders +[5] 

Other Information

ATC CodeH01AC06
Related LinksWikipediaDrugBankKEGG